Lingyi Bio Honored as One of the 'Top 10 Innovative Companies in Precision Medicine for 2024'

As the "Healthy China" strategy continues to deepen, the healthcare industry is facing unprecedented development opportunities. On November 22, the "2024 China Health Industry Development Conference and the 4th Golden Cane Award Ceremony" was grandly held in Beijing. Lingyi (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "Lingyi Biotech") was honored with the "Golden Cane Award - Top 10 Innovative Enterprises in Precision Medicine for 2024". This recognition among many competing enterprises is a full affirmation of Lingyi Biotech's capabilities in the innovation of gene therapy drugs at the source.

 

The "Golden Cane Award" is a health industry award launched by Huaxia Times on the platform of the Huaxia Health Industry Development Conference and is known as the "Oscars of Human Health". The cane itself symbolizes support, and the establishment of the Golden Cane Award primarily hopes that the winning companies will continue to contribute to the cause of human health, allowing people to live healthily and freely without the need for a cane. At the same time, it aims to spread positive energy and promote the healthy development of the medical and healthcare industry.